Intra-articular etanercept treatment for severe diffuse pigmented villonodular knee synovitis;Trattamento intra-articolare con l'antagonista del TNFα etanercept nella sinovite villo-nodulare pigmentosa diffusa del ginocchio

Reumatismo

Volumn 58, Issue 4, 2006, Pages 268-274

  Fiocco, Ugo ^a   Sfriso, P ^a   Oliviero, F ^a   Sovran, F ^a   Scagliori, E ^a   Pagnin, E ^a   Vezzu M ^a   Cozzi, L ^a   Botsios, C ^a   Nardacchione, R ^a   Di Maggio, A ^a   Rubaltelli, L ^a   Giacometti, C ^a   Calabrese, F ^a   Todesco, S ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Etanercept; Intra articular treatment; Pigmented villonodular synovitis

Indexed keywords

CORTICOSTEROID; ETANERCEPT; HLA B27 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; INFORMED CONSENT; MALE; PIGMENTED VILLONODULAR SYNOVITIS; RATING SCALE; SPONDYLOARTHROPATHY; SYNOVECTOMY; CASE REPORT; INTRAARTICULAR DRUG ADMINISTRATION; KNEE; PREOPERATIVE CARE; SYNOVIUM; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, INTRA-ARTICULAR; KNEE JOINT; MALE; PREOPERATIVE CARE; RECEPTORS, TUMOR NECROSIS FACTOR; SYNOVIAL MEMBRANE; SYNOVITIS, PIGMENTED VILLONODULAR; TREATMENT OUTCOME;

EID: 34247101089     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jaffe HL, Lichtenstein L, Sutro CJ. Pigmented villonodularis synovitis: bursitis and tenosynovitis. Arch Pathol 1941; 31: 731-65.
2. Akgun I, Ogut T, Kesmezacar H, Dervisoglu S. Localized pigmented villonodular synovitis of the knee. Orthopedics 2003; 26: 1131-5.
3. Byers PD, Cotton RE, Deacon OW, Lowy M, Newman PH, Sissons HA, et al. The diagnosis and treatment of pigmented villonodular synovitis. J Bone Joint Surg Br 1968; 50: 290-305.
4. Ofluoglu O. Pigmented villonodular synovitis. Orthop Clin North Am 2006; 37: 23-33.
5. Flandry F, Hughston JC, McCann SB, Kurtz DM. Diagnostic features of diffuse pigmented villonodular synovitis of the knee. Clin Orthop 1994; 298: 212-20.
6. Aigner T, Oehler S, Niedobitek HG, Fassbender G, Kirchner T. Iron deposits, cell populations and proliferative activity in pigmented villonodular synovitis of the knee joint. Verh Dtsch Ges Pathol 1998; 82: 327-31.
7. Neale SD, Kristelly R, Gundle R, Quinn JM, Athanasou NA. Giant cells in pigmented villonodular synovitis express an osteoclast phenotype. J Clin Pathol 1997; 50: 605-8.
8. Ray RA, Morton CC, Lipinski KK, Corson JM, Fletcher JA.Cytogenetic evidence of clonality in a case of pigmented villonodular synovitis. Cancer 1991; 67: 121-5.
9. Shabat S, Kollender Y, Merimsky O, Isakov J, Flusser G, Nyska M, et al. The use of surgery and yttrium 90 in the management of extensive and diffuse pigmented villonodular synovitis of large joints. Rheumatology 2002; 41: 1113-8.
10. Perka C, Labs K, Zippel H, Buttgereit F. Localized pigmented villonodular synovitis of the knee joint: neoplasma or reactive granuloma? A review of 18 cases. Rheumatol 2002; 39: 172-8.
11. Layfeld LJ, Meloni-Ehring A, Liu K, Shepard R, Harrelson JM. Malignant giant cell tumor of synovium (malignant villonodular synovitis). Arch Pathol Lab Med 2000; 124: 1636-41.
12. Fassbender HG. Pathology and Pathobiology of Rheumatic Diseases. Berlin-Heidelberg-New York: Springer, 2002.
13. Berger I, Weckauf H, Helmchen B, Ehemann V, Penzel R, Fink B, et al. Rheumatoid arthritis and pigmented villonodular synovitis: comparative analysis of cell polyploidy, cell cycle phases and expression of macrophage and fibroblast markers in proliferating synovial cells. Histopathology 2005; 46: 490-7.
14. Berger I, Paessler HH, Weckauf1 H, Ehemann1 V, Helmchen B. Strong expression of Bcl-2 in pigmented villonodular synovitis of the knee with aggressive clinical behaviour. Scand J Rheumatol 2005; 34: 68-70.
15. Berger I, Aulmann S, Ehemann V, Helmchen B, Weckauf H. Apoptosis resistance in pigmented villonodular synovitis. Histol Histopathol 2005; 20: 11.
16. Ijiri K. Increased expression of humanin peptide in diffusetype pigmented villonodular synovitis: implication of its mitochondrial abnormality Ann Rheum Dis 2005; 64: 816-23.
17. Guo B, Zhai D, Cabezas E, Welsh K, Niourain S, Tatterthwait A, et al.Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 2003; 423: 456-61.
18. West BR, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, et al. Landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 2006; 103: 690-5.
19. O'Keefe RJ, Rosier RN, Teot LA, Stewart JM, Hicks DG. Cytokine and matrix metalloproteinase expression in pigmented villonodular synovitis may mediate bone and cartilage destruction. Iowa Orthop J 1998; 18: 26-34.
20. Yoshida W, Uzuki M, Kurose A, Yoshida M, Nishida J, Shimamura T, et al. Cell characterization of mononuclear and giant cells constituting pigmented villonodular synovitis. Hum Pathol 2003; 34: 65-73.
21. Kroot EJ, Kraan MC, Smeets TJ, Maas M, Tak PP, Wouters JM. Tumour necrosis factor alpha blockade in treatment resistant pigmented villonodular synovitis. Ann Rheum Dis 2005; 64: 497-9.
22. Fiocco U, Ferro F, Vezzo M, Cozzi L, Checchetto C, Sfriso P, et al. Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power doppler ultrasound assessment of the response to etanercept. Ann Rheum Dis 2005; 64: 899-905.
23. Thompson PW, Silman AJ, Kirwan JR, Currey LF. Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis Rheum 1987; 30: 618-23.
24. Fiocco U, Cozzi L, Rigon C, Chieco-Bianchi F, Baldovin M, Cassisi GA, et al. Arthroscopic synovectomy in rheumatoid and psoriatic knee joint synovitis: long-term outcome. Br J Rheumatol 1996; 35: 463-70.
25. Helmchen B, Weckauf H, Ehemann V, Wittmann I, Meyer-Scholten C, Berger I. Expression pattern of cell cycle-related geneproducts in synovial stroma and synovial lining in active andquiescent stages of rheumatoid arthritis. Histol Histopathol 2005; 20: 365-72.
26. Finis K, Sultmann H, Ruschhaupt M, Buness A, Helmchen B, Kuner R, et al. Analysis of pigmented villonodular synovitis with genome-wide complementary DNA microarray and tissue array technology reveals insight into potential novel therapeutic approaches. Arthritis Rheum 2006; 54: 1009-19.
27. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
28. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90.
29. Osborn TG. Intraarticular etanercept versus saline in rheumatoid arthritis: a single injection double blind placebo controlled study. Arthritis Rheum 2002; 46 Suppl 9: 1385: S518.
30. Bliddal H, Qvistgaard E, Terslev L, et al. Injection of etanercept into arthritic joints. I° : safety. Ann Rheum Dis 2002, 61 (suppl 1); 29: 169.
31. Bliddal H, Qvistgaard E, Terslev L et al. Injection of etanercept into arthritic joints. II° : dose-response and efficacy. Ann Rheum Dis 2002; 61(suppl 1), 97: 38.
32. Buch M, Conaghan PG, Quinn MA, Bingham SJ, Veale DJ, Emery P. True infliximab resistance in rheumatoid arthritis; a role for lymphotoxin alfa?. Ann Rheum Dis 2004; 62: 783-4.
33. Fiocco U, Sfriso P, Cozzi L, Vezzù M, Cecchetto C, Todesco S, et al. Combined intra-articular etanercept treatment and extended arthroscopic synovectomy for severe pigmented villonodular knee synovitis. Ann Rheum Dis 2006; 65: 261.